Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Express Scripts
UBS
Covington
Harvard Business School
McKinsey
Deloitte
Mallinckrodt
Chinese Patent Office
Merck

Generated: January 20, 2018

DrugPatentWatch Database Preview

MAXALT Drug Profile

« Back to Dashboard

Which patents cover Maxalt, and what generic alternatives are available?

Maxalt is a drug marketed by Merck and is included in two NDAs.

The generic ingredient in MAXALT is rizatriptan benzoate. There are twenty-two drug master file entries for this compound. Twenty-nine suppliers are listed for this compound. Additional details are available on the rizatriptan benzoate profile page.

US Patents and Regulatory Information for MAXALT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-001 Jun 29, 1998 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-002 Jun 29, 1998 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-002 Jun 29, 1998 AB RX Yes Yes ➤ Subscribe ➤ Subscribe ➤ Subscribe
Merck MAXALT-MLT rizatriptan benzoate TABLET, ORALLY DISINTEGRATING;ORAL 020865-001 Jun 29, 1998 AB RX Yes No ➤ Subscribe ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for MAXALT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-001 Jun 29, 1998 ➤ Subscribe ➤ Subscribe
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-001 Jun 29, 1998 ➤ Subscribe ➤ Subscribe
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-002 Jun 29, 1998 ➤ Subscribe ➤ Subscribe
Merck MAXALT rizatriptan benzoate TABLET;ORAL 020864-002 Jun 29, 1998 ➤ Subscribe ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for MAXALT
Drugname Dosage Strength RLD Submissiondate
➤ Subscribe Orally Disintegrating Tablets 5 mg and 10 mg ➤ Subscribe 2/17/2006
➤ Subscribe Tablets 5 mg and 10 mg ➤ Subscribe 9/2/2004

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Deloitte
Harvard Business School
Farmers Insurance
Moodys
US Department of Justice
Queensland Health
Novartis
UBS
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot